Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK2 | P49760 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | IGF1R | P08069 | 5/20 | 0.42 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22828374 | 0.84 | STING1 (0.55) | P2RY1NPC1RAB9ATRPV1NTRK1 | |
| SCHEMBL23719252 | 0.80 | TP53 (0.52) | NPC1RAB9AROCK2NTRK1MAPT | |
| SCHEMBL22828406 | 0.79 | KMT2A (0.62) | RAB9ANTRK1MAPT | |
| SCHEMBL22828674 | 0.79 | RAB9A (0.62) | DYRK1ANPC1RAB9ATRPV1NTRK1 | |
| SCHEMBL23719139 | 0.77 | ROCK2 (0.40) | NPC1RAB9AROCK2NTRK1KDM4E | |
| SCHEMBL22236081 | 0.76 | CLK2 (0.68) | CLK2DYRK1ANPC1RAB9AMAPT | |
| SCHEMBL23719246 | 0.73 | CNR1 (0.43) | ROCK2MAPTKDM4E | |
| SCHEMBL22049637 | 0.72 | CLK2 (0.58) | CLK2DYRK1AIGF1RP2RY1RAB9A | |
| SCHEMBL22049829 | 0.71 | CLK2 (0.54) | CLK2DYRK1AP2RY1RAB9ATRPV1 | |
| SCHEMBL22828216 | 0.71 | KMT2A (0.52) | NPC1RAB9ATRPV1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230106899-A1 | METHODS OF TREATING CANCER | NOVARTIS PHARMA AG (CH) | 2023-04-06 | — | — | US | disclosed |
| US-20210236466-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2021-08-05 | — | — | US | disclosed |
| WO-2020257621-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210236466-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | CLK2 1343/4885DYRK1A 4056/4885IGF1R 2592/4885 |
| US-20230106899-A1 | METHODS OF TREATING CANCER | STING1, CGAS, TBK1 | CLK2 867/4885DYRK1A 2647/4885IGF1R 3134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.